BLAINJECTIONINJECTABLEPriority Review
Approved
May 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 20h ago
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Started May 2026
160 enrolled
Small Cell Lung Cancer
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
Started Apr 2026
48 enrolled
Extensive Stage Lung Small Cell Cancer
Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
Started Apr 2026
39 enrolled
Extensive Stage Lung Small Cell Carcinoma
Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab
Started Dec 2025
87 enrolled
Advanced Neuroendocrine Carcinomas of The Digestive SystemAdvanced Neuroendocrine Carcinomas Unknown Primary Origin
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
Started Nov 2025
70 enrolled
GliomaCNS Tumor, AdultCNS Tumor, Childhood
Worked on IMDELLTRA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.